Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients
Article first published online: 18 DEC 2008
Copyright © 2009 Wiley-Liss, Inc.
International Journal of Cancer
Volume 124, Issue 10, pages 2341–2346, 15 May 2009
How to Cite
Erfurt, C., Müller, E., Emmerling, S., Klotz, C., Hertl, M., Schuler, G. and Schultz, E. S. (2009), Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients. Int. J. Cancer, 124: 2341–2346. doi: 10.1002/ijc.24235
- Issue published online: 16 MAR 2009
- Article first published online: 18 DEC 2008
- Accepted manuscript online: 18 DEC 2008 12:00AM EST
- Manuscript Accepted: 19 NOV 2008
- Manuscript Received: 7 AUG 2008
- T helper cells;
- tumor antigen
Melanoma-associated chondroitin sulfate proteoglycan (MCSP) (also known as high molecular weight-melanoma-associated antigen) represents an interesting target antigen for cancer immunotherapy which is expressed on human melanomas and other tumors such as breast carcinomas, gliomas, neuroblastomas and acute leukemias. MCSP seems to play an important functional role in melanoma as it is involved in tumor cell migration, invasion and angiogenesis. In this study, we isolated CD4+ T helper cells from the blood of a healthy donor, recognizing a peptide from the MCSP core protein presented by HLA-DBR1*1101 molecules. T cell reactivity against the identified peptide could be detected in the blood of healthy donors and melanoma patients. MCSP specific T cells from the blood of a patient could be readily expanded by repeated peptide stimulation and recognized MCSP and HLA-DR expressing tumor cells. Our findings suggest that vaccination against MCSP helper T cell epitopes might be a promising approach to fight melanoma. © 2009 Wiley-Liss, Inc.